Skip to main content

Advertisement

SpringerLink
Log in

Clinicopathological features of breast cancers predict the development of leptomeningeal metastases: a case-control study

  • Clinical Study – Patient Study
  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Abstract

The incidence of leptomeningeal metastases (LM) in patients with breast cancer (BC) is increasing as a result of increased screening and improved patient survival. However, the median survival time after diagnosis of LM is between 5 weeks (without any treatment) and 5 months (for aggressively treated patients). In an attempt to identify clinicopathological risk factors for LM, we carried out a case-control study of 100 women with BC. Fifty patients with BC and LM were enrolled and an additional 50 patients with BC and no CNS metastases including leptomeningeal spread were selected as controls. Patients who had developed LM were selected between December 2006 and August 2008. The control group was matched for: age at diagnosis, year of diagnosis, and initiation of chemotherapy at BC diagnosis. The ILC type (P = 0.03), ER-negative (P = 0.01) and PR-negative status (P = 0.03), and initial M+ status at BC diagnosis (P = 0.008) tended to be more frequent in LM patients. These characteristics should lead to early appropriate assessments being performed in this targeted population when a neurological complaint appears, in order to detect LM as soon as possible.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Boogerd W (1996) Central nervous system metastasis in breast cancer. Radiother Oncol 40:5–22

    Article  PubMed  CAS  Google Scholar 

  2. Tosoni A, Franceschi E, Brandes AA (2008) Chemotherapy in breast cancer patients with brain metastases: Have new chemotherapic agents changed the clinical outcome? Crit Rev Oncol Hematol 68(3):212–221

    Article  PubMed  Google Scholar 

  3. Groves MD (2010) New strategies in the management of leptomeningeal metastases. Arch Neurol 67(3):305–312

    Article  PubMed  Google Scholar 

  4. Chamberlain MC (2009) Leptomeningeal metastasis. Curr Opin Neurol 22(6):665–674

    Google Scholar 

  5. Lin NU, Bello JR, Winer EP (2004) CNS metastases in breast cancer. J Clin Oncol 22:3608–3617

    Article  PubMed  Google Scholar 

  6. Elston CW, Elis IO (1991) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19(5):403–410

    Article  PubMed  CAS  Google Scholar 

  7. Wolff AC, Hammond ME, Schwartz JN, American Society of Clinical Oncology/College of American Pathologists et al (2007) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25(1):118–145

    Article  PubMed  CAS  Google Scholar 

  8. Krauseneck P (1998) Clinical relevance and current problems of neoplastic meningosis. J Neurooncol 38:93–95

    Article  PubMed  CAS  Google Scholar 

  9. Gonzales-Angulo AM, Cristofanilli M, Strom EA et al (2004) Central nervous system metastases in patients with high-risk breast carcinoma after multimodality treatment. Cancer 101:1760–1766

    Article  Google Scholar 

  10. Altundag K, Bondy ML, Mirza ND et al (2007) Clinicopathologic characteristics and prognostic factors in 420 metastatic breast cancer patients with central nervous system metastasis. Cancer 110:2640–2647

    Article  PubMed  CAS  Google Scholar 

  11. Chamberlain MC (1998) Leptomeningeal metastases: a review of evaluation and treatment. J Neurooncol 37:271–284

    Article  PubMed  CAS  Google Scholar 

  12. Chang EL, Maor MH (2003) Standard and novel radiotherapeutic approaches to neoplastic meningitis. Curr Oncol Rep 5(1):24–28 (review)

    Article  PubMed  Google Scholar 

  13. Li CI, Daling JR, Malone KE (2003) Incidence of invasive breast cancer by hormone receptor status from 1992 to 1998. J Clin Oncol 21(1):28–34

    Article  PubMed  CAS  Google Scholar 

  14. Evans AJ, James JJ, Cornford EJ et al (2004) Brain metastases from breast cancer: identification of a high-risk group. Clin Oncol 16(5):345–349

    Article  CAS  Google Scholar 

  15. Ryberg M, Nielsen D, Osterlind K et al (2005) Predictors of central nervous system metastasis in patients with metastatic breast cancer: a competing risk analysis of 579 patients treated with epirubicin-based chemotherapy. Breast Cancer Res Treat 91(3):217–225

    Article  PubMed  Google Scholar 

  16. Tham YL, Sexton K, Kramer R, Hilsenbeck S, Elledge R (2006) Primary breast cancer phenotypes associated with propensity for central nervous system metastases. Cancer 107:696–704

    Article  PubMed  Google Scholar 

  17. Slimane K, Andre F, Delaloge S et al (2004) Risks factors for brain relapse in patients with metastatic breast cancer. Ann Oncol 15(11):1640–1644

    Article  PubMed  CAS  Google Scholar 

  18. Wolstenholme V, Hawkins M, Ashley S, Tait D, Ross G (2008) HER2 significance and treatment outcomes after radiotherapy for brain metastases in breast cancer patients. Breast 17(6):661–665

    Article  PubMed  Google Scholar 

  19. Davoli A, Hocevar BA, Brown TL (2010) Progression and treatment of HER2-positive breast cancer. Cancer Chemother Pharmacol 65(4):611–623

    Article  PubMed  CAS  Google Scholar 

  20. Lai R, Dang C, Malkin M, Abrey L (2004) The risk of central nervous system metastases after trastuzumab therapy in patients with breast carcinoma. Cancer 101:810–816

    Article  PubMed  CAS  Google Scholar 

  21. Orvieto E, Maiorano E, Bottiglieri L et al (2008) Clinicopathologic characteristics of invasive lobular carcinoma of the breast: results of an analysis of 530 cases from a single institution. Cancer 113(7):1511–1520

    Article  PubMed  Google Scholar 

  22. Rakha EA, El-Sayed ME, Green AR, Lee AH, Robertson JF, Ellis IO (2007) Prognostic markers in triple negative breast cancer. Cancer 109(1):25–32

    Article  PubMed  CAS  Google Scholar 

  23. Basu S, Chen W, Tchou J et al (2008) Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization. Cancer 112(5):995–1000

    Article  PubMed  CAS  Google Scholar 

  24. Schnitt SJ, Guidi AJ (2004) Pathology of invasive breast cancer. In: Harris JR, Lippman ME, Morrow M, Osborne CK (eds) Disease of the breast cancer, vol 34, 3rd edn. Lippincott, Williams and Wilkins, Philadelphia, pp 541–584

  25. Clarke JL, Perez HR, Jacks LM, Panageas KS, DeAngelis LM (2010) Leptomeningeal metastases in the MRI era. Neurology 74:1449–1454

    Article  PubMed  CAS  Google Scholar 

Download references

Conflict of interest

No conflict of interest to declare for any author.

Author information

Authors and Affiliations

  1. Neurology-Breast Unit, Department of Medical Oncology, Centre Oscar Lambret, 59037, Lille Cedex, France

    Emilie Le Rhun

  2. Neuro-oncology, Department of Neurosurgery, Hopital Roger Salengro, Centre Hospitalier Régional et Universitaire, 59020, Lille Cedex, France

    Emilie Le Rhun & François Dubois

  3. Department of Neurology Mazarin and Department of Radiotherapy, Hopital La Pitié Salpétrière, Assistance Publique des Hôpitaux de Paris, Université Pierre et Marie Curie, Paris VI, 75013, Paris, France

    Sophie Taillibert

  4. Department of Neurosurgery, Hopital Roger Salengro, Centre Hospitalier Régional et Universitaire, 59020, Lille Cedex, France

    Fahed Zairi & Richard Assaker

  5. Department of Biostatistics, Centre Hospitalier Régional et Universitaire, 59020, Lille Cedex, France

    Patrick Devos

  6. University of Lille Nord de France, 59000, Lille Cedex, France

    Patrick Devos, Richard Assaker & Jacques Bonneterre

  7. Department of Radiology, Centre Oscar Lambret, 59037, Lille Cedex, France

    Matthieu Faivre Pierret

  8. Department of Medical Information, Centre Oscar Lambret, 59 037, Lille Cedex, France

    Etienne Buisset

  9. Breast Unit, Department of Medical Oncology, Centre Oscar Lambret, 59037, Lille Cedex, France

    Jacques Bonneterre

  10. Department of Pathology, Centre Oscar Lambret, 59020, Lille Cedex, France

    Marie Christine Baranzelli

  11. Department of Neurology, Centre Oscar Lambret, 2 rue Emile Laine, 59020, Lille Cedex, France

    Emilie Le Rhun

Authors
  1. Emilie Le Rhun
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sophie Taillibert
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Fahed Zairi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Patrick Devos
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Matthieu Faivre Pierret
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. François Dubois
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Richard Assaker
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Etienne Buisset
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Jacques Bonneterre
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Marie Christine Baranzelli
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Emilie Le Rhun.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Le Rhun, E., Taillibert, S., Zairi, F. et al. Clinicopathological features of breast cancers predict the development of leptomeningeal metastases: a case-control study. J Neurooncol 105, 309–315 (2011). https://doi.org/10.1007/s11060-011-0592-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11060-011-0592-7

Keywords

Search

Navigation